The “Fifth Middle East and North Africa Immuno-Oncology Forum (MIOF)”: March 8, 2024


Activity Director

Hazem Assi, MD (Chair, AUBMC)

Program Overview

MIOF is designed to cover all aspects of Immuno-oncology practices, with a specific focus on both solid tumors and hematological malignancies. This dynamic forum features leaders in the Oncology field, along with certified healthcare professionals, pharmacists, and nurses. Through engaging and interactive scientific sessions, these experts will delve into a diverse array of diagnostic and therapeutic advancements within the scope of immune-oncology. This visionary initiative seeks to bring together the diverse research and business communities in the field, providing a unified platform for oncologists, hematologists, research scholars, and students to exchange their knowledge. The program will focus on the most effective initiatives and best practices in treating both solid and liquid tumors.

Target Audience

This forum is designed for physicians in all specialties, specifically for Hematologists, Oncologists, Pathologists, and Gynecologists. Fellows, residents, nurses, pharmacists, medical students and all healthcare professionals related to this field are welcome to attend. For the detailed program please click here.

Program Objectives

At the end of this forum, participants will be able to:

  • Explore the criteria for selecting eligible candidate patients for immunotherapy.
  • Discuss the integration of molecular profiling and biomarkers in identifying patients who are most likely to benefit from immunotherapeutic interventions.
  • Emphasize personalized approaches that consider individual patient profiles and tumor characteristics.
  • Identify the most effective modalities for immunotherapies, considering both single-agent and combination approaches tailored to specific tumor conditions.
  • Evaluate the variability, benefits, and drawbacks of immunotherapy in comparison to traditional treatment modalities.
  • Investigate and analyze the spectrum of side effects and toxicities associated with immunotherapies.
  • Work towards standardizing protocols and guidelines for administrating immunotherapies in the treatment of solid tumors and hematological malignancies.